The global cancer pain market accounted for a market size of USD 6,716.2 Million in 2021 and is projected to reach USD 9,951.2 Million by 2030, at a growth rate of 4.6% during the forecast period.
The global cancer pain market is expected to grow owing to various factors such as the niche penetration of healthcare facilities for cancer diagnostics coupled with the rising healthcare expenditure & government support worldwide. Furthermore, growing prevalence of cancer pain is also estimated to boost the market growth. According to the National Cancer Institute, as of December 2021, around 20-50% cancer patients suffer from pain. Also, according to the Centers for Disease Control and Prevention (CDC), roughly 15.5 million cancer survivors (those who have had a cancer diagnosis) were alive in the United States in 2016, with that figure predicted to rise to over 20 million by 2026. Despite the driving factors, accessibility to facilities and high cost of treatment are expected to hinder the market growth during the forecast period.
Rising healthcare expenditure and government support worldwide
With the growing prevalence of cancer, the awareness for the disease as well as the associated pain is also increasing. This is also leading to the rising healthcare expenditure for diagnosis and treatment of the cancer associated pain. According to the OECD, the preliminary estimates of healthcare spending for a group of 16 OECD countries jumped to about 9.9% of GDP in 2020. Therefore, the rising healthcare expenditure and government support worldwide is anticipated to fuel the market growth.
The global cancer pain market is segmented the drug type and disease indication.
The opioids/narcotics segment is estimated to account for the largest market share of approximately 75% owing to the growing prevalence of cancer pain and the growing product pipeline. Within this segment, the codeine sub-segment is expected to witness the highest CAGR of 5.5%. This is because codeine is required in less amount as compared to the other opioids. In addition, the non-opioids segment is estimated to account for a market opportunity of around USD 482.7 million during 2022 to 2030. Within this segment, the non-steroidal anti-inflammatory drugs (NSAIDS) segment is estimated to surpass a market size of USD 1,000 million by 2022. This is because of the low cost as well as easy availability of these drugs.
The breast cancer segment is expected to witness the fastest growth rate of 5.5% during the forecast period and is also estimated to account for the largest market share of around 16% in 2021, owing to the increasing prevalence of breast cancer. According to the World Health Organization (WHO), there were around 2.3 million women diagnosed with breast cancer in 2020. As per the same source, about 685,000 deaths occurred globally in 2020, due to breast cancer. On the other hand, the colorectal cancer segment accounted for the lowest revenue of USD 549.5 million by 2030.
Based on region, the global Cancer pain market is divided into Europe, North America, Asia Pacific, South America, and the Middle East & Africa.
The North America region is expected to hold the largest market share of around 42% in 2021. This amounted to a market size of USD 2,834.8 million. This is owing to the growing incidence rate of cancer and presence of various market players in the region. In the U.S. around 1,194 people below the age of 20 years were suffering from cancer pain in 2021. Total number of people suffering from cancer pain in 2021 in the country was 1,16,182. Also, this number was expected to reach 1,743 people below the age of 20 and 1,59,889 total population suffering from cancer pain by 2030.
Asia Pacific region witnessed the fastest growth rate of 5.7% during the forecast period owing to the easy availability of pain therapeutics, growing geriatric population, and rising awareness of cancer.
Key players operating in the global cancer pain market include Orexo AB, MundiPharma International Ltd., Biodelivery Sciences International Inc., Hisamitsu Pharma Co., Teva Pharma Industries Ltd., CK life Science (WEX Pharma), Daiichi Sankyo Co., Pfizer Inc., Roche Holding AG, and Other Prominent Players. The cumulative market share of 4 major players is near about 35%.
These market players are involved in collaborations, mergers & acquisitions, and new product launches to strengthen their market presence. For instance, in December 2021, Pfizer collaborated with Amazon Web Services, Inc. (AWS) for creating cloud-based solutions for improving the development, manufacturing, and distribution of medicines for clinical trials testing. The company enhanced the company’s position in the market.
Marketed and Emerging Drugs
There are many marketed drugs in the market by various companies. For instance, ULTRAM (tramadol hydrochloride) by Janssen Ortho, LLC; Hydromorphone Hydrochrloride by Janssen Korea, Ltd, Oxycodone by Taiwan Mundipharma Pharmaceuticals Ltd, and Lazanda (Fentanyl) by Insys Therapeutics, Inc., among others.
Many market players are also investing in various research and development activities for development of more effective drugs for the treatment of cancer pain. Some of the emerging drugs include Morphine sulfate by Tetra Biopharma/Cognitive Research Corporatio, Resiniferatoxin by Sorrento Therapeutics, Inc., and Pregabalin by Institut Cancerologie de l'Ouest/Grünenthal GmbH. Sorrento’s resiniferatoxin received FDA clearance for proceeding with its Phase 2 clinical study for using epidural resiniferatoxin for treatment of intractable pain associated with advanced cancer.
The global cancer pain market is expected to grow owing to various factors such as the niche penetration of healthcare facilities for cancer diagnostics coupled with the rising healthcare expenditure & government support worldwide. Furthermore, growing prevalence of cancer pain is also estimated to boost the market growth. According to the National Cancer Institute, as of December 2021, around 20-50% cancer patients suffer from pain. Also, according to the Centers for Disease Control and Prevention (CDC), roughly 15.5 million cancer survivors (those who have had a cancer diagnosis) were alive in the United States in 2016, with that figure predicted to rise to over 20 million by 2026. Despite the driving factors, accessibility to facilities and high cost of treatment are expected to hinder the market growth during the forecast period.
Growth Influencers:
Rising healthcare expenditure and government support worldwide
With the growing prevalence of cancer, the awareness for the disease as well as the associated pain is also increasing. This is also leading to the rising healthcare expenditure for diagnosis and treatment of the cancer associated pain. According to the OECD, the preliminary estimates of healthcare spending for a group of 16 OECD countries jumped to about 9.9% of GDP in 2020. Therefore, the rising healthcare expenditure and government support worldwide is anticipated to fuel the market growth.
Segments Overview:
The global cancer pain market is segmented the drug type and disease indication.
By Drug Type,
- Opioids/ Narcotics
- Hydromorphone (Dilaudid)
- Morphine (Kadian, M-Eslon Others)
- Codeine
- Oxycodone
- Tramadol
- Fentanyl
- Others
- Non-Opioids
- Acetaminophen
- Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)
- Nerve Blocks
The opioids/narcotics segment is estimated to account for the largest market share of approximately 75% owing to the growing prevalence of cancer pain and the growing product pipeline. Within this segment, the codeine sub-segment is expected to witness the highest CAGR of 5.5%. This is because codeine is required in less amount as compared to the other opioids. In addition, the non-opioids segment is estimated to account for a market opportunity of around USD 482.7 million during 2022 to 2030. Within this segment, the non-steroidal anti-inflammatory drugs (NSAIDS) segment is estimated to surpass a market size of USD 1,000 million by 2022. This is because of the low cost as well as easy availability of these drugs.
By Disease Indication,
- Lung Cancer
- Colorectal Cancer
- Breast Cancer
- Prostate Cancer
- Blood Cancer
- Others
The breast cancer segment is expected to witness the fastest growth rate of 5.5% during the forecast period and is also estimated to account for the largest market share of around 16% in 2021, owing to the increasing prevalence of breast cancer. According to the World Health Organization (WHO), there were around 2.3 million women diagnosed with breast cancer in 2020. As per the same source, about 685,000 deaths occurred globally in 2020, due to breast cancer. On the other hand, the colorectal cancer segment accounted for the lowest revenue of USD 549.5 million by 2030.
Regional Overview
Based on region, the global Cancer pain market is divided into Europe, North America, Asia Pacific, South America, and the Middle East & Africa.
The North America region is expected to hold the largest market share of around 42% in 2021. This amounted to a market size of USD 2,834.8 million. This is owing to the growing incidence rate of cancer and presence of various market players in the region. In the U.S. around 1,194 people below the age of 20 years were suffering from cancer pain in 2021. Total number of people suffering from cancer pain in 2021 in the country was 1,16,182. Also, this number was expected to reach 1,743 people below the age of 20 and 1,59,889 total population suffering from cancer pain by 2030.
Asia Pacific region witnessed the fastest growth rate of 5.7% during the forecast period owing to the easy availability of pain therapeutics, growing geriatric population, and rising awareness of cancer.
Competitive Landscape
Key players operating in the global cancer pain market include Orexo AB, MundiPharma International Ltd., Biodelivery Sciences International Inc., Hisamitsu Pharma Co., Teva Pharma Industries Ltd., CK life Science (WEX Pharma), Daiichi Sankyo Co., Pfizer Inc., Roche Holding AG, and Other Prominent Players. The cumulative market share of 4 major players is near about 35%.
These market players are involved in collaborations, mergers & acquisitions, and new product launches to strengthen their market presence. For instance, in December 2021, Pfizer collaborated with Amazon Web Services, Inc. (AWS) for creating cloud-based solutions for improving the development, manufacturing, and distribution of medicines for clinical trials testing. The company enhanced the company’s position in the market.
Marketed and Emerging Drugs
There are many marketed drugs in the market by various companies. For instance, ULTRAM (tramadol hydrochloride) by Janssen Ortho, LLC; Hydromorphone Hydrochrloride by Janssen Korea, Ltd, Oxycodone by Taiwan Mundipharma Pharmaceuticals Ltd, and Lazanda (Fentanyl) by Insys Therapeutics, Inc., among others.
Many market players are also investing in various research and development activities for development of more effective drugs for the treatment of cancer pain. Some of the emerging drugs include Morphine sulfate by Tetra Biopharma/Cognitive Research Corporatio, Resiniferatoxin by Sorrento Therapeutics, Inc., and Pregabalin by Institut Cancerologie de l'Ouest/Grünenthal GmbH. Sorrento’s resiniferatoxin received FDA clearance for proceeding with its Phase 2 clinical study for using epidural resiniferatoxin for treatment of intractable pain associated with advanced cancer.
The global Cancer pain market report provides insights on the below pointers:
- Market Penetration: Provides comprehensive information on the market offered by the prominent players
- Market Development: The report offers detailed information about lucrative emerging markets and analyzes penetration across mature segments of the markets
- Market Diversification: Provides in-depth information about untapped geographies, recent developments, and investments
- Competitive Landscape Assessment: Mergers & acquisitions, certifications, product launches in the global cancer pain market have been provided in this research report. In addition, the report also emphasizes the SWOT analysis of the leading players.
- Product Development & Innovation: The report provides intelligent insights on future technologies, R&D activities, and breakthrough product developments
- Cancer Market Growth Forecast (USD Million), 2017-2030
- Epidemiology & Patient Population; 8MM Incident Patient Population of Cancer Pain
- Country Wise Epidemiology of Cancer Pain: U.S., EU5 (Germany, France, Italy, Spain, and the UK), Japan, China, and India
- Treatment & Management of Cancer Pain: Treatment Guidelines, WHO Guidelines for Cancer Pain Management. ESMO Guidelines for Cancer Pain Management
- Marketed Drugs: ULTRAM (Tramadol Hydrochloride)-Janssen Ortho, LLC - Product Description, Other Development Activities, Clinical Development, Clinical Trials Information, Safety & Efficacy, Product Profile; Hydromorphone Hydrochloride (HCl)-Janssen Korea, Ltd; Oxycodone-Taiwan Mundipharma Pharmaceuticals Ltd; Lazanda (Fentanyl)-Insys Therapeutics, Inc.
- Emerging Drugs: Morphine Sulfate-Tetra Biopharma/Cognitive Research Corporation-Product Description, Regulatory Milestones, Clinical Development, Ongoing Current Pipeline Activity, Safety & Efficacy, product Profile; Resiniferatoxin-Sorrento Therapeutics, Inc.; Pregabalin-Institut Cancerologie de I’Quest/Grunenthal GmbH
The global Cancer pain market report answers questions such as:
- What is the market size and forecast of the Global Cancer pain Market?
- What are the inhibiting factors and impact of COVID-19 on the Global Cancer pain Market during the assessment period?
- Which are the products/segments/applications/areas to invest in over the assessment period in the Global Cancer pain Market?
- What is the competitive strategic window for opportunities in the Global Cancer pain Market?
- What are the technology trends and regulatory frameworks in the Global Cancer pain Market?
- What is the market share of the leading players in the Global Cancer pain Market?
- What modes and strategic moves are considered favorable for entering the Global Cancer pain Market?
Table of Contents
Chapter 1. Research Framework
Chapter 3. Introduction
Chapter 4. Global Cancer Pain Market Overview
Chapter 5. Competition Dashboard
Chapter 6. Global Cancer Pain Market Analysis, By Drug Type
Chapter 7. Global Cancer Pain Market Analysis, By Disease Indication
Chapter 8. Global Cancer Pain Market Analysis, By Region/Country
Chapter 9. North America Cancer Pain Market Analysis
Chapter 10. Europe Cancer Pain Market Analysis
Chapter 11. Asia Pacific Cancer Pain Market Analysis
Chapter 12. Middle East & Africa Cancer Pain Market Analysis
Chapter 13. South America Cancer Pain Market Analysis
Chapter 14. The US Cancer Pain Market Analysis
Chapter 15. The UK Cancer Pain Market Analysis
Chapter 16. Germany Cancer Pain Market Analysis
Chapter 17. France Cancer Pain Market Analysis
Chapter 18. Italy Cancer Pain Market Analysis
Chapter 19. Spain Cancer Pain Market Analysis
Chapter 20. China Cancer Pain Market Analysis
Chapter 21. Japan Cancer Pain Market Analysis
Chapter 22. India Cancer Pain Market Analysis
Chapter 23. Company Profile (Company Overview, Financial Matrix, Key Product landscape, Key Personnel, Key Competitors, Contact Address, and Business Strategy Outlook)
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Aoxing Pharmaceutical Company, Inc.
- BioDelivery Sciences International, Inc.
- CK Life Sciences (WEX Pharmaceuticals)
- Daiichi Sankyo Co., Ltd.
- Hisamitsu Pharmaceutical Co., Inc.
- Mundipharma International Limited
- Orexo AB
- Pfizer Inc.
- Teva Pharmaceutical Industries Limited
- Roche Holding AG
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 278 |
| Published | January 2022 |
| Forecast Period | 2021 - 2030 |
| Estimated Market Value ( USD | $ 6716.2 Million |
| Forecasted Market Value ( USD | $ 9951.2 Million |
| Compound Annual Growth Rate | 4.5% |
| Regions Covered | Global |
